Recombinant Human FXYD domain-containing ion transport regulator 5 (FXYD5), partial

1. the ratio between FXYD5 and alpha1-beta1 heterodimer determines whether the Na,K-ATPase acts as a positive or negative regulator of intercellular adhesion. PMID: 27142834
2. Knockdown of FXYD5 in MDA-MB-231 breast cancer cells largely decreases expression and secretion of the chemokine CCL2 (MCP-1). A related effect has also been observed in renal cell carcinoma cells. PMID: 27006401
3. Study demonstrated that the expression of FXYD1, FXYD3 and FXYD5 is elevated in the lungs of Acute respiratory distress syndrome patients PMID: 26410457
4. Dysadherin-silenced side population cells exhibited reduced expression of Bcl-2 and Bax compared with that prior to silencing. PMID: 26458963
5. we are focusing on the role of dysadherin in E-cadherin downregulation, the various expression patterns of the molecule in head and neck cancer PMID: 22105147
6. Findings suggest that dysadherin might contribute to breast cancer progression through AKT activation. PMID: 22494103
7. These results suggest a role of let-7a down-regulation in the development of thyroid neoplasias of the follicular histotype, likely regulating dysadherin protein expression levels. PMID: 22965940
8. Data show that osteoblasts are the major cell type of the bone marrow that affect RCC cells by secreting factors that increase the expression of dysadherin and CCL2 in the tumor cells leading to enhanced cell migration. PMID: 21328336
9. This is the first report on expression of dysadherin in the male gonad and in spermatozoa. PMID: 21774927
10. Overexpression of Snail, Slug, and dysadherin and activation of Wnt and PI3K/Akt signaling was associated with inactivated E-cadherin in the spindle cells of monophasic fibrous synovial sarcomas. PMID: 21809991
11. Combined dysadherin-positive expression and E-cadherin-negative expression may be valuable information for predicting aggressive tumor behavior of differentiated-type gastric carcinoma with submucosal invasion PMID: 21239043
12. transfection of dysadherin cDNA into the liver cancer cell line PLC/PRF/5 enhanced the properties of cencer stem cells, including anti-apoptosis, their sphere-forming ability, side population phenotype, and tumor initiation ability in vivo PMID: 20952084
13. In lung carcinomas dysadherin expression seems to reflect tumour aggressiveness and may be considered a positive marker of poor prognosis when considered alone or/and in combination with down-regulation of E-cadherin. PMID: 20712010
14. The detection of dysadherin in tumors and cytokeratin in the lymph nodes may be a potential significant indicator of a poor prognosis for patients who undergo complete resection of stage I non-small cell lung cancer PMID: 20944097
15. We report the cloning and characterization of a cancer-associated cell membrane glycoprotein recognized by mAb NCC-3G10. PMID: 11756660
16. dysadherin expression was significantly associated with the prognosis, occurrence of secondary undifferentiated carcinomas, size of the primary tumor, and metastasis to the regional lymph nodes and lungs PMID: 12970317
17. dysadherin has a role in hematogenous metastasis of gastric cancer PMID: 15102690
18. Dysadherin and E-cadherin expression may help to predict the prognosis of patients with ESCC (esophageal squamous cell carcinoma). PMID: 15459499
19. Dysadherin is able to modulate actin structures, stimulate cell motility, and contribute directly to the metastatic potential of human pancreatic cancer cells. PMID: 15466191
20. dysadherin may be a valuable prognostic marker in cervical carcinoma. PMID: 15619642
21. Over expression of dysadherin is associated with cutaneous malignant melanoma PMID: 15751018
22. In testicular tumours, as in other neoplasms, dysadherin downregulates E-cadherin expression, at least in part PMID: 16333245
23. Found in trophoblasts in both normal and abnormal pregnancies. PMID: 17084448
24. Dysadherin may play an important role in breast cancer progression by promoting invasion. PMID: 17437014
25. Recent work that has provided insights into possible mechanisms of action of dysadherin in the cancer progression process was reviewed. PMID: 17442482
26. FXYD5 is upregulated in cystic fibrosis epithelia which may exacerbate the Na(+) hyperabsorption and surface liquid dehydration observed in cystic fibrosis. PMID: 18263667
27. Increased dysadherin expression is possibly one of the post-transcriptional mechanisms responsible for E-cadherin downregulation in thyroid papillary neoplasia PMID: 18677652
28. The dysadherin expression level was significantly correlated with gastrointestinal stromal tumor risk stratification. PMID: 19217217

Show More

Hide All

HGNC: 4029

OMIM: 606669

KEGG: hsa:53827

STRING: 9606.ENSP00000344254

UniGene: Hs.333418